Description

Montelukast Sodium (Leukotriene receptor antagonists (LTRAs))

• Montelukast, inhibits the actions of Cysteinyl-leukotrienes which is accountable for allergic response by blocking type 1 CysLT receptors in the respiratory mucosa.

• With a favorable safety profile montelukast, is a well-tolerated preventative treatment for allergic airway inflammation in patients with SAR or PAR without asthma, and in patients in whom AR is comorbid with asthma.

• Aspirin-intolerant patients have nasal polyps and that treatment with the leukotriene inhibitor montelukast has resulted in improvement and resolution of the polyps.

Fexofenadine Hydrochloride (Antihistamines)

• Fexofenadine HCl, the carboxylic acid metabolite of terfenadine, is a new second-generation antihistamine that is nonsedating and does not cause electrocardiographic effects. 

• H1-receptor antagonist is both effective and safe for the treatment of ragweed seasonal allergic rhinitis.

• Works by blocking a certain natural substance (histamine) synthesized by the body during an allergic reaction.

Acebrophylline (Bronchodilators)

• Acebrophylline is an airway mucus regulator with anti-inflammatory action. 

• Acebrophylline increases the synthesis and release of alveolar surfactant, resulting in triple action: mucoregulation, stimulation of bronchoalveolar clearance, and anti-inflammatory –anti-reactive effect.

• Acebrophylline acted sooner than ambroxol to improve pathological auscultation findings & relieve cough. 

• With stronger stimulation of pulmonary surfactant production and more effective mucoregulation, its action was significantly superior to that of ambroxol.

• Therapeutically effective in patients with chronic obstructive or asthma-like bronchitis:
• It reduces the frequency of episodes of bronchial obstruction and 
• Reduces the need for beta2-agonists, and 
• Improves indexes of ventilatory function.